Investigational drug · Phase 3
camrelizumab; famitinib malate
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cervical Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 9, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
10
Any phase or sponsor naming "camrelizumab; famitinib malate"
First trial start
2021
Jul 23, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "camrelizumab; famitinib malate", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cervical Cancer
Approved drugs for the same conditions: Cervical cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "camrelizumab; famitinib malate" as an intervention, largest first.
- A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05042375 · 450 participants (planned) · Start Sep 8, 2022 · Primary completion Dec 31, 2023
Drug: camrelizumab + famitinib; pembrolizumab and 1 more · For: Non-small Cell Lung Cancer
Sites: Bengbu, China; Hefei, China; Beijing, China · 80 sites in all
- Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical CancerPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04906993 · 443 participants · Start Jul 23, 2021 · Primary completion Jun 10, 2025
Drug: camrelizumab; famitinib malate; platinum-based chemotherapy · For: Cervical Cancer
Sites: Shanghai, China
- Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological TumorsStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03827837 · 265 participants (planned) · Start Jan 23, 2019 · Primary completion Dec 2022
Drug: SHR-1210; Famitinib · For: Renal Cell Carcinoma; Urothelial Carcinoma; Cervical Cancer and 2 more
Sites: Shanghai, China
- A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical CancerPivotal-lookingNot yet recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
NCT07143292 · 120 participants (planned) · Start Nov 30, 2025 · Primary completion Dec 30, 2026
Drug: Famitinib + Camrelizumab · For: Cervical Cancer Metastatic; Cervical Cancer Recurrent
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05214976 · 64 participants (planned) · Start Aug 12, 2022 · Primary completion Jan 31, 2023
Drug: Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound) · For: Advanced Solid Tumors
Sites: Shanghai, China
- A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.Status unknown
Shanghai Chest HospitalAcademic, hospital or other
NCT05005468 · 61 participants (planned) · Start Sep 2021 · Primary completion Aug 2023
Drug: Camrelizumab; Famitinib · For: NSCLC
Sites: Shanghai, China
- Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical CancerNot yet recruiting
Hunan Cancer HospitalAcademic, hospital or other
NCT07627620 · 54 participants (planned) · Start Jun 30, 2026 · Primary completion Sep 30, 2027
Drug: Camrelizumab; Famitinib Malate and 1 more · For: Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05208177 · 25 participants · Start Apr 22, 2022 · Primary completion Aug 18, 2023
Drug: SHR-1802+camrelizumab + famitinib · For: Advanced Solid Tumor
Sites: Tianjin, China
- A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLCPivotal-lookingTerminated
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05106335 · 1 participants · Start Jan 6, 2022 · Primary completion May 11, 2022
Drug: camrelizumab + famitinib; famitinib and 1 more · For: Advanced NSCLC
Sites: Yangzhou, China
- Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced OsteosarcomaWithdrawn
Peking University People's HospitalAcademic, hospital or other
NCT04044378 · 0 participants · Start Aug 15, 2019 · Primary completion Sep 30, 2021
Drug: Famitinib; Ifosfamide and 1 more · For: Effect of Drugs; Progression; Pediatric Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Cervical Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- SYS6002Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors
- JSKN033Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.